Common aspirin could ease breathing for millions with COPD
NCT ID NCT05265299
Summary
This study is testing which daily dose of aspirin (81mg, 162mg, or 325mg) best reduces blood cell inflammation linked to worse COPD symptoms. Researchers will enroll 48 adults with COPD who are former smokers. The goal is to find the most effective dose to inform a larger future trial on whether aspirin can reduce flare-ups and improve daily breathing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY DISEASE, CHRONIC OBSTRUCTIVE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins Bayview Medical Center
RECRUITINGBaltimore, Maryland, 21224, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.